Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers

• Published in: Oncotarget Vol. 7; no. 52; pp. 86687 - 86694
• Main Authors: Odén, Lovisa, Akbari, Mohammad, Zaman, Tasnim, Singer, Christian F, Sun, Ping, Narod, Steven A, Salmena, Leonardo, Kotsopoulos, Joanne
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 27-12-2016
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; BRCA1 Protein - genetics; BRCA2 Protein - genetics; Breast Neoplasms - blood; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Female; Heterozygote; Humans; Kaplan-Meier Estimate; Medicin och hälsovetenskap; Middle Aged; Mutation; Osteoprotegerin - blood; Proportional Hazards Models; Research Paper; Risk Assessment - methods; Risk Assessment - statistics & numerical data; Risk Factors; Young Adult; BRCA1/2; breast cancer; osteoprotegerin (OPG); receptor activator of nuclear factor κB (RANKL); chemoprevention
• DOI: 10.18632/oncotarget.13417
• EISSN: 1949-2553

Emerging evidence suggests a role of receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL) signaling in breast cancer development. Lower osteoprotegerin (OPG) levels, the endogenous decoy receptor for RANKL which competes with RANK for binding of RANKL, has been reported among BRCA mutation carriers. Whether low OPG levels contribute to the high breast cancer risk in this population is unknown. OPG concentrations were measured in plasma of 206 cancer-free BRCA mutation carriers using an enzyme-linked immunosorbent assay. Subjects were categorized as high vs. low based on the median of the entire cohort (95 ng/mL) and followed for a new diagnosis of breast cancer. Cumulative incidence by baseline plasma OPG concentration was estimated using Kaplan-Meier survival analysis. Cox proportional hazards models were used to estimate the adjusted hazard ratios for the association between plasma OPG and breast cancer risk. Over a mean follow-up period of 6.5 years (range 0.1-18.8 years), 18 incident breast cancer cases were observed. After ten years of follow-up, the cumulative incidence of breast cancer among women with low OPG was 21%, compared to 9% among women with high OPG (P-log rank = 0.046). After multivariate adjustment, women with high plasma OPG had a significantly decreased risk of developing breast cancer, compared to women with low OPG (HR = 0.25; 95%CI 0.08-0.78; P = 0.02). These data suggest that low OPG levels are associated with an increased risk of BRCA-associated breast cancer. Targeting RANK signalling may represent a plausible, non-surgical prevention option for BRCA mutation carriers.